Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 60.00p 55.00p 65.00p 60.00p 55.00p 55.00p 0.00 08:00:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.1 -6.5 -56.2 - 11.21

Genedrive Share Discussion Threads

Showing 1 to 16 of 25 messages
Chat Pages: 1
DateSubjectAuthorDiscuss
22/11/2016
09:44
To be clear, I am not a big investor in AIM stocks, Epistem/GDR is my only one, into which I was enticed several years ago. I sold at a loss last year but retain the company on my watch list. Cepheids system is not ldentical to GDR, however they are blessed with a dynamic development team and have many peer reviewed publications out there, yet they are still not breaking into the Indian market Last week I had a day in the Madica conference in Germsny which supports the clinical manufCturing and diagnostic companies. All I could find out about GDR is that they are ploughing ahead with the technology as it stands, though the one delegate who knew the company claimed that they had been working with a big multi national who advised them to make changes to their design and work flow a few years ago. These recommendations were turned down by the old CEO and scientific director apparently. I couldn't find out any more as I had other fish to fry!
azzi
21/11/2016
21:50
Very interesting comment about the Indian political system, I hadn't considered that angle, it can be a tough place to do business. Even the established leader in this TB Dx space, Cepheid, have faced a mountain of difficulties, all of which Genedrive needs to overcome: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967565/ Furthermore, these innovative TB diagnostic platforms have not helped patients at all- there has been no improvement in patient outcome despite these technological offerings. The doctors out in the field are hugely experienced and are not stupid- if it looks like you've got TB then you'll be treated like you've got TB. They dont and wont wait for a GeneXpert or Genedrive to tell them what to do. Cepheid were acquired recently (hxxp://investors.danaher.com/2016-09-06-Danaher-To-Acquire-Cepheid-For-53-00-Per-Share-Or-Approximately-4-Billion) and cintinue to deveop and release next-generation instruments which compete directly with Genedrive
briansewell
21/11/2016
10:28
Thanks Brian for your informative post. Admit, I had to teach myself about isothermal DNA amplification, to simplify, it is a way of amplifying DNA without the need for significant heating and cooling steps required for PCR which is the technology on which Genedrive is based. I have no idea if this company are modifying their platform to run isothermal assays. Remember this would need development of isothermal assays also, frankly Epistem appear transfixed with what they have, hence my critical comments about their R&D, I don't think they have the in house capability to progress, and have to agree that they are being left behind. If I were the CEO, I would be seriously looking to either contract out, or partner with a respected R&D outfit. They have little time left so need to make a move now. I have also been critical of their belief that the Indian political system will accept a system that potentially threatens Indian jobs.....it's a long story.
azzi
18/11/2016
13:16
From what I could find out, the IL28 assay is not a big potential seller at all. I thought the assay was already validated, I guess this news is confirmation? Only significant take up of the Tb assay in India will move the share price All other applications appear to have limited commercial potential.
azzi
11/10/2016
08:43
Read between the lines. Absolutely no uptake of the Tb assay in India. Clearly there are major problems with ease of use, the company claims to have tested the technology in many sites over the years, why are these problems only now becoming evident? I assume they have cherry picked the feedback to ensure they were able to hit their launch dates which has been a higher priority than the quality of the product. So, development continues, However I refer to my earlier post on the absence of quality R&D .
azzi
10/10/2016
21:20
I hope to see some concrete evidence that the Genedrive Tb assay is meeting the companies claims tomorrow. Only then will I consider re-investing.
azzi
25/9/2016
07:21
Waiting to see if anything in results. Watching it, as stated in previous.
the ghost who walks
23/9/2016
19:53
Yes, still watching. I hope the new CEO isn't just trying to impress the city with new appointments. All that matters is that the technology works, is cost effective and competitive in the market. I would have been more impressed if they had announced a new R&D director /consultant as I believe this is where the real weakness with this company lies. Please see my earlier post.
azzi
21/9/2016
15:23
Interesting update. Continuing to watch this one.
the ghost who walks
15/9/2016
13:28
monitoring this closely
the ghost who walks
09/9/2016
21:25
I also continue to monitor closely. I also stand by my previous post!
azzi
02/9/2016
17:52
Looking forward to the next updateMonitoring closely
the ghost who walks
25/8/2016
17:34
Monitoring the updates
the ghost who walks
22/8/2016
06:34
Closely following the updates
the ghost who walks
22/8/2016
06:34
Monitoring this one closely.
the ghost who walks
16/8/2016
18:23
No significant share price response at all to recent updates. The Tb assay is now scheduled for launch in 2017, BUT, the company must be aware of the feedback from its Indian distributors by now, remember this is their flag ship right now. On the face of it, positive news for their HCV/IL28 assay, however placing 20 gene drives and only 400 assays (that's 20 assays per gene drive!) is small scale proof of principle stuff, I thought they were way beyond that! It feels the company are drifting aimlessly, just hoping that a good result will emerge and provide a way forward. For me this is the problem, there is no obvious on going development/problem solving of their technology. Something has changed. It feels like they need some decent R&D input, I really don't think they have this right now, so it's time to go looking for the right people who can help them out of their malaise. For the record, I am still a potential investor, just need some real proof that they have worthwhile assay technology.
azzi
Chat Pages: 1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20161211 00:21:30